Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | CASP7 | P55210 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | ACACB | O00763 | 1/20 | 0.31 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.31 |
| ▸ | ITK | Q08881 | 1/20 | 0.30 |
| ▸ | TYK2 | P29597 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23325915 | 0.83 | HCAR3 (0.32) | HRH3HCAR3 | |
| SCHEMBL25908867 | 0.83 | ITK (0.31) | ITK | |
| SCHEMBL23324957 | 0.69 | ACACB (0.34) | ACACBHCAR3 | |
| SCHEMBL24127267 | 0.68 | ALDH1A1 (0.40) | HRH3KMT2AALDH1A1CYP1A2HPGD | |
| SCHEMBL25905785 | 0.68 | ADRA2A (0.40) | KMT2AALDH1A1ACACBHCAR3 | |
| SCHEMBL23325913 | 0.68 | HCAR3 (0.61) | ALDH1A1HCAR3 | |
| SCHEMBL23324958 | 0.63 | HCAR3 (0.32) | HCAR3 | |
| SCHEMBL25318819 | 0.62 | ALDH1A1 (0.40) | KMT2AUSP2ALDH1A1CYP1A2GLA | |
| SCHEMBL23341625 | 0.61 | TSHR (0.36) | KMT2AALDH1A1 | |
| SCHEMBL11961046 | 0.59 | ADORA3 (0.44) | KMT2AALDH1A1CYP1A2HPGDCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234929-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| US-11566007-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2023-01-31 | — | — | US | disclosed |
| US-20210130303-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11566007-B2 | Ras inhibitors | KRAS, NRAS, HRAS | HRH3 3696/4885KMT2A 3685/4885USP2 1149/4885 |
| US-20230234929-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | HRH3 3696/4885KMT2A 3685/4885USP2 1149/4885 |
| US-20210130303-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | HRH3 3696/4885KMT2A 3685/4885USP2 1149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.